

Arkansas Department of Health

4815 West Markham Street • Little Rock, Arkansas 72205-3867 • Telephone (501) 661-2000 Governor Mike Beebe Nathaniel Smith, MD, MPH, Interim Director and State Health Officer

<u>Summary of Proposed Changes to</u> Rules and Regulations Pertaining to the List of Controlled Substances for the State of Arkansas

The Department of Health proposes to amend the Rules and Regulations Pertaining to the List of Controlled Substance for the State of Arkansas.

The purpose of the amendment is to update the list to:


- Incorporate revisions to Schedule VI enacted by the Arkansas Legislature in Act 329 of 2013;
- Include drugs added to the schedule by the U.S. Department of Justice Drug Enforcement Agency (DEA); and
- Include a drug added to the schedule by emergency rule.

The following additions are proposed to the List.

On May 22, 2013, Dr. Nathaniel Smith, Interim Director and State Health Officer, determined that 25C-NBOMe posed an imminent peril to public health, safety, or welfare and immediately classified the substance as Schedule I (#35, page 4) pursuant to Ark. Code Ann. § 5 64 201. The Department was notified by the Washington County Office of the Prosecuting Attorney that the substance was found in a synthetic hallucinogenic product tested by the Arkansas State Crime Lab.

Since the last update of the List of Controlled Substances, the Department of Justice Drug Enforcement Agency (DEA) has added several substances to Schedule I (#36 - #44, page 4). In addition, DEA added Lorcaserin to Schedule IV (#13, page 14).

Act 329 of 2013 was passed by the Arkansas Legislature to amend Schedule VI. Changes from Act 329 are incorporated so that Schedule VI conforms to the Act (pages 17 - 21).



STATE OF ARKANSAS CONTROLLED SUBSTANCES LIST May 22 , 2013

Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Director of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Director of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Director of the Arkansas Department of Health.

I, James Myatt, P.D., Branch Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

> James Myatt, P.D., Chief Pharmacy Services Branch

STATE OF ARKANSAS

COUNTY OF SALINE

I, <u>Marci Middleton</u>, do hereby certify that James Myatt, P.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this 22nd day of May, 2013.

))

)

Notary Public

My commission expires

ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Stat. Ann. \$5-64-201 and \$5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

In accordance with Ark. Code Ann. § 5-64-414(c), the Washington County Office of the Prosecuting Attorney notified the Director of the Department of Health that an analog to a substance on the List of Controlled Substance was found in a synthetic hallucinogenic product tested by the State Crime Laboratory.

The Director of the Department of Health and Secretary for the Arkansas State Board of Health finds imminent peril to public health, safety, or welfare requiring the adoption of the following rule upon fewer than thirty (30) days' notice. It is found and determined by the Director of the Department of Health and the Secretary of the Arkansas State Board of Health that 25C-NBOMe is an analog of 2C-B, an existing substance found in Schedule I of the List of the Controlled Substances, and should be immediately classified as a Schedule I Controlled Substance.

Wherefore, the Director of the Department of Health and Secretary for the Arkansas State Board of Health specifically finds that 2-(4-chloro-2,5dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine or 25C-NBOMe has a high potential for abuse and has no accepted medical use in treatment in the United States and should be immediately classified as a Schedule I Controlled Substance pursuant to Ark. Code Ann. § 5-64-201.

Therefore, an emergency is hereby declared to exist and this Rule, being necessary for the immediate preservation of the public peace, health and safety, shall be in full force and effect from and after May 22, 2013.

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the day of , 2013, and after a Public Hearing on the day of , 2013, held in Little Rock, Arkansas at the State Department of Health Building.

Nathaniel Smith, M.D., MPH Interim Director, Arkansas Department of Health

ARTICLE II

Schedule I

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Opiates:** (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of paragraph (b) (34) only, the term isomer includes the optical and geometric isomers):

(1)	Acetyl-alpha-methylfentanyl(N-[1-[1-methyl-2-	
	phenethyl)-4-piperidinyl]-N-phenylacetamide)	9815-(2-86)
(2)	Acetylmethadol	9601*
(3)	Allylprodine	9602*
(4)	Alphacetylmethadol (except Levo-alphacetylmethadol	
	(LAAM)	
(5)	Alphameprodine	9604*
(6)	Alphamethadol	
(7)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-pheny	yl)
	ethyl-4-piperidyl]propronanilide; 1-(1-methyl-	
	2-phenylethyl)-4(N-propanilido)piperidine)	9814-(6-82)
(8)	Alpha-methylthiofentanyl(N-[1-methyl-2-(2thienyl)	
	ethyl-4-piperidinyl]-N-phenylpropanamide)	
(9)	Benzethidine	
(10)	Betacetylmethadol	9607*
(11)	Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenethyl)	
	-4-piperidinyl[]-N-phenylpropanamide)	9830-(2-86)
(12)	Beta-hydroxy-3-methylfentanyl	
	[other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl	
	4-piperidinyl]-N-phenylpropamamide]	9831-(2-86)
(13)	Betameprodine	9608*
(14)	Betamethadol	9609*
(15)	Betaprodine	
(16)	Clonitazene	
(17)	Dextromoramide	
(18)	Diampromide	
(19)	Diethylthiambutene	9616*
(20)	Difenoxin	
(21)	Dimenoxadol	
(22)	Dimepheptanol	
(23)	Dimethylthiambutene	
(24)	Dioxaphetyl butyrate	9621*
(25)	Dipipanone	
(26)	Ethylmethylthiambutene	
(27)	Etonitazene	
(28)	Etoxeridine	
(29)	Furethidine	
(30)	Hydroxypethidine	9627*
(31)	Ketobemidone	
(32)	Levomoramide	9629*
(33)	Levophenacylmorphan	9631*
(34)	3-Methylfentanyl (N-[3-Methyl-1-(2-phenylethyl)-4-	
	piperidyl]-N-Phenylpropanamide)	9813-(10-85)

(35)	3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)	
	ethyl-4-piperidinyl]-N-phenylpropanamide)	9833-(2-86)
(36)	Morpheridine	
(37)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	
(38)	Noracymethadol	
(39)	Norlevorphanol	9634*
(40)	Normethadone	9635*
(41)	Norpipanone	
(42)	Para-fluorofentanyl (N-[4-fluorophenyl)-N-[1-(2-	
()	phenenthyl)-4-piperindinyl]propananmide	9812-(11-86)
(43)	PEPAP 1-(2-phenylethyl)-4-phenyl-4 acetyloxypiper-	, , , , , , , , , , , , , , , , , , ,
. ,	idine	9663-(10-85)
(44)	Phenadoxone	
(45)	Phenampromide	9638*
(46)	Phenomorphan	
(47)	Phenoperidine	9641*
(48)	Piritramide	9642*
(49)	Proheptazine	9643*
(50)	Properidine	
(51)	Propiram	9649*
(52)	Racemoramide	9645*
(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-	
	piperidinyl]-propanamide	9835-(2-86)
(54)	Tilidine	9750-(9-81)
(55)	Trimeperidine	9646*

(c) **Opium derivatives:** (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Acetorphine	9319*
(2)	Acetyldihydrocodeine	9051*
(3)	Benzylmorphine	9052*
(4)	Codeine methylbromide	9070*
(5)	Codeine-N-Oxide	9053*
(6)	Cyprenorphine	9054*
(7)	Desomorphine	9055*
(8)	Dihydromorphine	9145*
(9)	Drotebanol	9335*
(10)	Etorphine (except hydrochloride salt)	9056*
(11)	Heroin	9200*
(12)	Hydromorphinol	9301*
(13)	Methyldesorphine	9302*
(14)	Methyldihydromorphine	9304*
(15)	Morphine methylbromide	9305*
(16)	Morphine methylsulfonate	9306*
(17)	Morphine-N-Oxide	9307*
(18)	Myrophine	9308*
(19)	Nicocodeine	9309*
(20)	Nicomorphine	9312*
(21)	Normorphine	9313*
(22)	Pholcodine	9314*
(23)	Thebacon	9315*

(d) **Hallucinogenic substances**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence

of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers): alpha-ethyltryptamine ----- 7249-(12-93) (1)Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; and AET. 4-bromo-2,5-dimethoxy-amphetamine ----- 7391* (2) Some trade or other names: 4-bromo-2,5-dimethoxyalpha-methylphenethylamine; 4-bromo-2,5-DMA. 4-bromo-2,5-dimethoxyphenethylamine ----- 7392-(8-95) (3) Some trade or other names: 2-(4-bromo-2,5- dimethoxyphenyl)-1 aminoethane; alpha-desmethyl DOB; 2C-B, Nexus. 2,5-dimethoxyamphetamine ----- 7396* (4) Some trade or other names: 2,5-dimethoxy-alphamethylphenethylamine; 2,5-DMA. (5) 2,5-dimethoxy-4-ethylamphetamine ----- 7399-(3-88) Some trade or other names: DOET. (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine----- 7348-(1-05) Some trade or other names: 2C-T-7. (7) 4-methoxyamphetamine ----- 7411* Some trade or other names: 4-methoxy-alphamethylphenethylamine; paramethoxyamphetamine; PMA. (8) 5-methoxy-3,4-methylenedioxy-amphetamine ----- 7401* 4-methyl-2,5-dimethoxyamphetamine ----- 7395* (9) Some trade and other names: 4-methyl-2,5-dimethoxyalphamethylphenethylamine; "DOM"; and "STP". 3,4-methylenedioxy amphetamine ----- 7400* (10)(11) 3,4-methylenedioxymethamphetamine ----- 7405-(10-85) Some trade or other names: MDMA) (12)3,4-methylenedioxy-N-ethylamphetamine ----- 7404-(6-90) Some trade or other names: N- ethy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA; MDE; MDEA. N-hydroxy-3,4-methylenedioxyamphetamine ----- 7402-(6-90) (13)Some trade or other names: N-hydroxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine; N-hydroxy MDA 3,4,5-trimethoxy amphetamine ----- 7390* (14)5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT----- 7431*(01-11) (15)alpha-methyltryptamine ----- 7432-(7-05) (16)Some trade or other names: AMT Bufotenine ----- 7433* (17)Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine. Diethyltryptamine ----- 7434* (18)Some trade or other names: N, N-Diethyltryptamine; DET. Dimethyltryptamine ----- 7435* (19)Some trade or other names: DMT 5-methoxy-N,N-diisopropyltryptamine ----- 7439-(7-05) (20)Some trade or other names: 5-MeO-DIPT. Ibogaine ----- 7260* (21)Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9, 10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1',2': 1,2] azepino [5,4-b] indole; Tabernanthe iboga. (22) Lysergic acid diethylamide ----- 7315*

(23)	Mescaline	7381*
(24)	Parahexyl	7374-(7-83)
	Some trade or other names: 3-Hexyl-1-hydroxy-	
	7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo	
	[b,d] pyran; Synhexyl.	
(25)	Peyote	7415*
	Meaning all parts of the plant presently classified	
	botanically as Lophophora williamsii Lemaire, whether	2
	growing or not; the seeds thereof; any extract from	
	any part of such plant; and every compound,	
	manufacture, salts, derivative, mixture or	
	preparation of such plant, its seeds or extracts.	
	(Interprets 21 USC 812 (c), Schedule I (c) (12)).	
(26)	N-ethyl-3-piperidyl benzilate	7482*
(27)	N-methyl-3-piperidyl benzilate	7484*
(28)	Psilocybin	7437*
(29)	Psilocyn	
(30)	Ethylamine Analog of phencyclidine	7455*
	Some trade or other names:	
	N-ethyl-1-phenylcyclohexylamine,	
	<pre>(phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)</pre>	
	ethylamine; cyclohexamine; PCE.	
(31)	Pyrrolidine Analog of phencyclidine	7458*
	Some trade or other names: 1-(1-phenylcyclohexyl)-	
	pyrrolidine; PCPy; PHP	
(32)	Thiophene Analog of phencyclidine	7470*
	Some trade or other names: 1-[1-(2-thienyl)	
	cyclohexyl] Piperidine; 2-Thienyl analog of	
	phencyclidine; TPCP; TCP.	
(33)	1-[1-(2-Thienyl)cylcohexyl]pyrrolidine	7473-(9-89)
	Some other trade or other names: TCPy.	
(34)	N,N-Diallyl-5-Methoxytryptamine; 5-MeO DALT	
(35)	2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)	<u> </u>
	methyl]ethanamine; 25C-NBOMe	
(36)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E	
(37)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D	7508
(38)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C	
(39)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I	7518
(40)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine;	
	<u>2C-T-2</u>	7385
(41)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine;	
	2C-T-4	7532
(42)	2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H	7517
(43)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; 2C-N	7521
(44)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;	7504
	2C-P	7524

(e) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Phenazepam

- (2) gamma-hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxydutanoic acid; sodium oxybate; sodium oxybutyrate), and its known precursors and analogs -- 2010-(2-01)
- (3) Mecloqualone ----- 2572*

(4) Methaqualone ----- 2565*

(f) <u>Stimulants</u>: (a)Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1)	Cathinone	1235-(3-88)
(2)	(+) CIS-4-Methylaminorex [(+)CIS-4,5-dihydro-4-	
	methyl-5-phenyl-2-oxazolamine]	1590-(6-90)
(3)	Fenethylline	
(4)	N-Benzylpiperazine	7493-(1-05)
	Some trade or other names: BZP, 1-Benzylpiperazine	
(5)	N-ethylamphetamine	1475-(6-82)
(6)	N-[1-(1-benzyl-4-piperidyl]-N-phenylpropanamide	
	(benzylfentanyl), its optical isomers, salts and	
	salts of isomers	9818-(2-86)
(7)	N-[1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropan-	
	mide (thenylfentanyl), its optical isomers, salts	
	and salts of isomers	9834-(2-86)
(8)	N, N, Dimethylamphetamine (some other names: N, N	
	Alpha-trimethylbenzeneethanamine; N, N, Alpha-	
	trimethylphenethylamine), its salts, optical	1400 (2.00)
(0)	isomers, and salts of optical isomers	1480-(2-89)
(9)	Methcathinone (some other names:	
	2-Methylamine-Proprophenone, alpha (methylamino)- Proprophenone, 2 (methylamino)-1-phenylpropan-1-one,	
	alpha-N-Methylaminopropiophenone, monomethylpropion,	
	ephedrone, N-methylcathinone, methycathinone, AL-464,	
	AL-422, AL-463 and UR-1431), its salts, optical	
	isomers and salts of optical isomers	1237-(12-93)
(10)	Aminorex (some other names: aminoraphen, 2-amino-5	120, (12, 50)
(,	phenyl-2-oxazoline, or 4,5 dihyrdo-5-phenyl-2-	
	oxazolamine, its salts, optical isomers, and salts	
	of optical isomers	1585-(12-93)
(b)		
directly or	indirectly from a substance of vegetable origin or in	-
means of ch	emical synthesis or by a combination of extraction and	chemical
synthesis,	that contains any quantity of the following substances	, or that

isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I:

ture	is in	icluded in Schedule I:	
(1)	4-M	Methylmethcathinone (Mephedrone)	1248-(3-11)
(2)	Met	hylenedioxypyrovalerone (MDPV)	(3-11)
(3)	3,4	-Methylenedioxy-N-methylcathinone (Methylone)	7540-(3-11)
(4)		Methoxymethcathinone	
(5)		luoromethcathinone	
(6)	4-F	luoromethcathinone or	(3-11)
(7)	Ac	compound, unless listed in another schedule or a	
	leg	end drug, that is structurally derived from	
	2-A	mino-phenyl-1-propanone by modification or by	
	sub	ostitution:	
	(A)	In the phenyl ring to any extent with alkyl,	
		alkoxy, alkylenedioxy, haloalkyl or halide	
		substituents, whether or not further	
		substituted in the phenyl ring by one (1) or	
		more other univalent substituents;	
	(B)	At the 3-position with an alkyl substituent; or	

contains any of the following substances' analogs, salts, isomers, and salts of

(C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

Schedule II

(a) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.

(b) **Narcotic Drugs:** Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone and their respective salts, but including the following:

(1)	Raw opium	9600*
(2)	Opium extracts	9610*
(3)	Opium fluid extracts	9620*
(4)	Powdered opium	9639*
(5)	Granulated opium	9640*
(6)	Tincture of opium	9630*
(7)	Codeine	9050*
(8)	Dihydroetorphine	9334*
(9)	Ethylmorphine	
(10)	Etorphine hydrochloride	
(11)	Hydrocodone	
(12)	Hydromorphone	
(13)	Metopon	
(14)	Morphine	
(15)	Oripavine	
(16)	Oxycodone	9143*
(17)	Oxymorphone	9652*
(18)	Thebaine	9333*
(19)	Tapentadol	9780-(5-09)

- (2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.*
- (3) Opium poppy and poppy straw.*
- (4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.*
- (5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of the opium poppy), 9670.*

(c) **Opiates:** (Narcotic Drugs) Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of

such isomers, esters, ethers, and salts is possible within the specific chemical designations:

JIIacion		
(1)	Alfentanil	
(2)	Alphaprodine	
(3)	Anileridine	
(4)	Bezitramide	
(5)	Bulk Dextropropoxyphene (non-dosage forms)	9273-(9-81)
(6)	Carfentanil	9743-(9-88)
(7)	Dihydrocodeine	
(8)	Diphenoxylate	9170*
(9)	Fentanyl	9801*
(10)	Isomethadone	
(11)	Levo-alphacetylmethadol (LAAM)	9648-(12-93)
(12)	Levomethorphan	9210*
(13)	Levorphanol	
(14)	Metazocine	9240*
(15)	Methadone	9250*
(16)	Methadone-Intermediate, 4-cyano-2-	
	dimethylamino-4, 4-diphenyl butane	9254*
(17)	Moramide-Intermediate, 2-methyl-3-	
	morpholino-1, 1-diphenylpropane-	
	carboxylic acid	
(18)	Pethidine (Meperidine)	9230*
(19)	Pethidine-Intermediate-A, 4-cyano-1-	
	methyl-4-phenylpiperidine	9232*
(20)	Pethidine-Intermediate-B, ethyl-4-	
	phenylpiperidine-4-carboxylate	9233*
(21)	Pethidine-Intermediate-C, 1-methyl-4-	
	phenylpiperidine-4-carboxylic acid	9234*
(22)	Phenazocine	9715*
(23)	Piminodine	
(24)	Racemethorphan	
(25)	Racemorphan	
(26)	Remifentanil	
(27)	Sufentanil	9740-(9-81)

(d) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

(1)	Amphetamine, its salts, optical isomers, and salts	
	of its optical isomers	1100*
(2)	Methamphetamine, its salts, isomers, and salts	
	of its isomers	1105*
(2)	Tiedeneme fetemine	1005+17 (

- (3) Lisdexamefetamine ----- 1205*(7-07)
 (4) Phenmetrazine and its salts ----- 1631*
- (5) Methylphenidate ----- 1724*

(e) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Amobarbital	2125*
(2)	Glutethimide	2550-(2-91)
(3)	Pentobarbital	2270*
(4)	Phencyclidine	7471*
(5)	Secobarbital	2315*

(f) Hallucinogenic Substances:

(1) Nabilone ----- 7379-(11-87) [Another name for nabilone: (+))trans-3-(1,1dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pran-9-one].

(g) <u>Immediate Precursor</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

- (1) Immediate precursor to Amphetamine and Methamphetamine:
 - (i) Phenylacetone ----- 8501-(3-80) Some trade or other names: phenyl-2-propanone;
 - P2P; benzyl methyl Ketone; methyl benzyl Ketone.
- (2) Immediate precursor to Phencyclidine (PCP):(i) 1-phenylcyclohexylamine ----- 7460*
 - (ii) 1-piperidinocyclohexanecarbonitrile (PCC) ----- 8603*
- (3) Immediate precursor to Fentyl:
 - (i) 4-anilino-n-phenethyl-4-piperidine(ANPP) ----- 8333*(08-10)

Schedule III

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances------ 1405*
 Benzphetamine ------ 1228*
- (3) Chlorphentermine ----- 1645*
- (4) Clortermine ----- 1647*
- (5) Phendimetrazine ----- 1615*

(c) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:

(i)	Amobarbital	2126*
(ii)	Secobarbital	2316*
(iii)	Pentobarbital	2271*
(iv)	Embutramide	2020*(9-06)
	or any salt thereof and one or more other	
	active medicinal ingredients which are not	

.....

listed in any schedule. Any suppository dosage form containing: (2) (i) Amobarbital ----- 2126* (ii) Secobarbital ----- 2316* (iii) Pentobarbital ----- 2271* or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository. (3) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof---- 2100* (4) Chlorhexadol ----- 2510* (5) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act----- 2012-(2-01) (6) Ketamine. its salts, isomers, and salts of isomers--- 7285-(7-99) Some other names for Ketamine: (+-)-2-(2-Chlorophenyl)-2-(Methylamino)-Cyclohexanone. (7) Lysergic acid ----- 7300* (8) Lysergic acid amide ----- 7310* (9) Methyprylon ----- 2575* (10) fondiethylmethane ----- 2600* (11) Sulfonethylmethane ----- 2605* (12) Sulfonmethane ----- 2610* (13) Tiletamine and zolazepam or any salt thereof ----- 7295-(3-88) Some trade or other name for a tiletaminezolazepam combination product: Telazol. Some trade or other names for tiletamine: -2 (ethylamino) -2- (2-thienyl) -cyclohexanone. Some trade or other names for zolazepam: -4(2-fluorophenyl)-6,8-dihydro-1,3,8,trimethylpyrazolo-[3,4-e] [1,4,]-diazepin-7 (1-H)-one. flupyrazapon. Nalorphine ----- 9400* (d) Narcotic drugs: Unless specifically excepted or unless listed in another (e) schedule: (1) any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: Not more than 1.8 grams of codeine per 100 (i) milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium ----- 9803* Not more than 1.8 grams of codeine per 100 (ii) milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9804* (iii) Not more than 300 milligrams of dihydrocodeinone(hydrocodone) per 100 milliliters or not more than 15 milligrams

per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of

		opium	9805*
	(iv)	Not more than 300 milligrams of dihydrocodeinone(hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active non-	
		narcotic ingredients in recognized therapeutic amounts	9806*
	(v)	Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active	
		nonnarcotic ingredients in recognized therapeutic amounts	9807*
	(vi)	Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized	9007
	(vii)	therapeutic amounts Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more	
	(viii	active nonnarcotic ingredients in recognized therapeutic amounts)Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized	9809*
(2)	conta	therapeutic amounts aterial, compound, mixture, or preparation ining any of the following narcotic drugs or salts, as set forth below:	9810*
		Buprenorphine	9064-(6-85) (10-02 Transfer)
		_	

(ii) Reserved

Anabolic Steroids: Unless specifically excepted or unless listed in (f) another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: Items 1-28 ------ 4000-(9-91)

- (1) Boldenone;
- (2) Boldione; (01-10)
- (3) Chlorotestosterone (4-chlortestosterone);
 (4) Clostebol;
- (5) Dehydrochlormethyltestosterone;
- (6) Desoxymethyltestosterone (01-10)
- (7) Dihydrotestosterone (4-dihydrotestosterone);
- (8) Drostanolone;
- (9) Ethylestrenol;
- (10) Fluoxymesterone;
- (11) Formebulone (formebolone);
- (12) Mesterolone;
- (13) Methandienone;
- (14) Methandranone;
- (15) Methandriol;
- (16) Methandrostenolone;
- (17) Methenolone;
- (18) Methyltestosterone;
- (19) Mibolerone;
- (20) Nandrolone;
- (21) 19-Nor-4,9(10)-Androstadienedione (01-10)

(22) Norethandrolone; (23) Oxandrolone;

		Uxandrolone;	
		Oxymesterone;	
	(25)	Oxymetholone;	
	(26)	Stanolone;	
	(27)	Stanozolol;	
	(28)	Testolactone;	
	(29)	Testosterone;	
	(30)	Trenbolone; and	
	(31)	Any salt, ester, or isomer of a drug or	
		substance described or list in this paragraph,	
		if that salt, ester, or isomer promotes muscle	
		growth.	
(1)	Exem	pt anabolic steroid products: Compounds,	
(=)		ures, or preparations that contain an anabolic	
		oid that have been exempted by the Director:	
			NDC Number
	(1)	Andro-Estro 90-4	
	(2)	Androgyn L.A	
	(3)	Component E-H in Process Pellets	
	(4)	Component E-H in Process Granulation	Ioha Ing
	(4)	depANDROGYN	1405 1020
		Depo-Testadiol	
	(6)	DEPO-T.E	
	(7)	depTESTROGEN	
	(8)	deptestrogen	
	(9)	DUO-SPAN II	
		DUC-SPAN II	
	• •		43/9/-016
	(12)	Esterfied Estrogens & Methyltestosterone (1.25mg/2.5mg)	Turkerunkeru
	(1 2)		Interpham
	(13)	Esterfied Estrogens & Methyltestosterone (0.625mg/1.25mg)	
	(1.4)		ANDAPHarm
	(14)	Esterfied Estrogens & Methyltestosterone (1.25mg/2.5mg)	ANDA Dh a mm
	(1 5)	(1.25mg/2.5mg) Estratest	
		Estratest HS	
	(17)	-	
	(18) (19)		59254-560
	(19)	Methyltestosterone & Esterfied Estrogens (2.5mg/1.25Mg)	Lannatt CO
	(20)		Lannett CO
	(20)	Methyltestosterone & Esterfied Estrogens (1.25mg/0.625mg)	Lannatt CO
	(21)	(1.25mg/0.825mg) PAN ESTRA TEST	
	(21)	Premarin with Methyltestosterone	
	(22)	Premarin with Methyltestosterone	
	(23)	Syntest D.S	0046 - 0878
	(24)	Syntest D.SStntest H.S	
	(25)		
	(26)	Synovex H in process bulk pellets	
	(27)	Synovex H in process granulation	
	(28)	Synovex Plus in process granulation	
	(29)	Synovex Plus in process bulk pellets Testagen	
	(30)	TestagenTestagenTEST-ESTRO Cypionates	
	(31)		
	(32)	Testoderm with adhesive 4mg/d	
	(33)	Testoderm 4mg/d	
	(34)	Testoderm 6mg/d	
	(35)	Testoderm with Adhesive 6mg/d	
	(36)	Testoderm in process film	
	(37)	Testoderm with Adhesive in process film	Alza Corp.

	(38)	Testosterone Cypionate/Estradiol Cypionate	
	(39)	<pre>injection Testosterone Cypionate/Estradiol Cypionate</pre>	542/4-530
	(00)	injection	
	(40)	Testosterone Cyp 50 Estradiol Cyp2	0814-7737
	(41)	Testosterone Cypionate/Estradiol Cypionate	
		injection	0364-6611
	(42)	Testosterone Cypionate/Estradiol Cypionate	
		injection	0402-0257
	(43)	Testosterone Cypionate/Estradiol Cypionate	
		injection	0404-0257
	(44)	Testosterone Enanthate/Estradiol Valerate	
		injection	0182-3073
	(45)	Testosterone Enanthate/Estradiol Valerate	
		injection	0364-6618
	(46)	Testosterone Enanthate/Estradiol Valerate	
		injection	
		Testosterone Ophthalmic Solution	
		Tilapia Sex Reversal Feed (investigational)	Ranger, Inc.
(2)		rinary Anabolic Steroid Implant Products:	
		olic steroid products expressly intended for	
		nistration through implants in cattle or other	
	nonhı	uman species exempted by the Director.	
			NDC/DIN
	(1)	Component E-H	021641-002
	(2)	Component E-H	021641-002 01968327
	(2) (3)	Component E-H Component TE-S	021641-002 01968327 021641-004
	(2) (3) (4)	Component E-H Component TE-S Component T-H	021641-002 01968327 021641-004 0211641-006
	(2) (3) (4) (5)	Component E-H Component TE-S Component T-H Component T-S	021641-002 01968327 021641-004 0211641-006 0211641-005
	(2) (3) (4) (5) (6)	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351
	(2) (3) (4) (5) (6) (7)	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-10
	<pre>(2) (3) (4) (5) (6) (7) (8)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H Finaplix-S	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-10 12799-807-07
	<pre>(2) (3) (4) (5) (6) (7) (8) (9)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H Finaplix-S Heifer-old	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H Finaplix-S Heifer-old	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-07 Boehringer Ingelheim Ivy Lab.
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H	021641-002 01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO Finaplix-H	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen, Inc.
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen, Inc. 12799-811
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (12) (13) (14) (15) (16)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen,Inc. 12799-811 12799-810
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen,Inc. 12799-811 12799-810 12799-809
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen,Inc. 12799-811 12799-810 12799-809 0856-3901
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen,Inc. 12799-811 12799-810 12799-809 0856-3901 Syntex
	<pre>(2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20)</pre>	Component E-H Component TE-S Component T-H Component T-S F-TO	021641-002 01968327 021641-004 0211641-005 00093351 12799-807-10 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 01968327 Rangen,Inc. 12799-811 12799-810 12799-809 0856-3901 Syntex 0856-3904

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

- (g) <u>Hallucinogenic substances</u>:
 - (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product ----- 7369-(11-87) [Some other names for dronabinol: (6a R-trans)-6a,7,8, 10a-tetrahydro-6, 6,

```
9-trimethyl-3-pentyl-6H-dibenzo [b,d]
phyran-1-ol, or (-)-delta 9-(trans)-
tetrahydrocannabinol]
```

Schedule IV

(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **<u>Narcotic drugs</u>**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

- (1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine
- sulfate per dosage unit.---- 9167*
 (2) Dextro propoxyphene (alpha-(+)-4-dimethylamino-
- 1,2-diphenyl-3-methyl-2-propionoxybutane) ----- 9278-(11-87)

(c) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

within	the specific chemical designation:	
(1)	Alprazolam	
(2)	Barbital	
(3)	Bromazepam	
(4)	Camazepam	
(5)	Chloral betaine	
(6)	Chloral hydrate	
(7)	Chlordiazepoxide	
(8)	Clobazam	
(9)	Clonazepam	
(10)	Clorazepate	
(11)	Clotiazepam	
(12)	Cloxazolam	
(13)	Delorazepam	
(14)	Diazepam	
(15)	Dichloralphenazone	
(16)	Estazolam	
(17)	Ethchlorvynol	2540*
(18)	Ethinamate	
(19)	Ethyl loflazepate	
(20)	Fludiazepam	
(21)	Flunitrazepam	
(22)	Flurazepam	
(23)	Fospropofol	
(24)	Halazepam	
(25)	Haloxazolam	
(26)	Ketazolam	
(27)	Loprazolam	
(28)	Lorazepam	
(29)	Lormetazepam	
(30)	Mebutamate	
(31)	Medazepam	
(32)	Meprobamate	
(33)	Methohexital	2264*

(34)	Methylphenobarbital (mephorbarbital)	2250*
(35)	Midazolam	2884-(1-85)
(36)	Nimetazepam	2837-(1-85)
(37)	Nitrazepam	2834-(1-85)
(38)	Nordiazepam	2838-(1-85)
(39)	Oxazepam	2835*
(40)	Oxazolam	2839*
(41)	Paraldehyde	2585*
(42)	Petrichloral	2591*
(43)	Phenobarbital	2285*
(44)	Pinazepam	2883-(1-85)
(45)	Prazepam	2764*
(46)	Quazepam	2881-(11-86)
(47)	Temazepam	2925-(9-81)
(48)	Tetrazepam	2886-(1-85)
(49)	Triazolam	2887-(7-83)
(50)	Zaleplon	2781-(9-99)
(51)	Zolpidem	2783-(12-93)
(52)	Zopiclone	2784-(01-06)

(d) <u>Fenfluramine</u>: Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

 (1) Fenfluramine ------ 1670*

(e) <u>Stimulants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Cathine ((+)-Norpseudeophedrine)	1230-(3-88)
(2)	Diethylpropion	1610*
(3)	Fencamfamin	1760-(3-88)
(4)	Fenproporex	1575-(3-88)
(5)	Mazindol	1605-(6-82)
(5)	Mefenorex	1580-(3-88)
(6)	Modafinil	1680-(1-99)
(7)	Pemoline (including organometallic complexes	
	and chelates thereof)	1530*
(9)	Phentermine	1640*
(10)	Pipradrol	1750-(9-81)
(11)	Sibutramine	1675-(2-98)
(12)	SPA ((-)-1-dimethylamino-1,2,diphenylethane)	1635-(9-81)
(13)	Lorcaserin	1625

(f) **Other substances**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1)	Pentazocine	9709-(4-79)
(2)	Carisoprodol	(4-97)
(3)	Butorphanol	9720-(4-97)
(4)	Nalbuphine	(4-97)
(5)	Tramadol	(8-07)

Schedule V

(a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) <u>Narcotic Drugs</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below. *Reserved*

(c) <u>Narcotic drugs containing nonnarcotic active medicinal ingredients.</u> Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

- * (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
- * (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
- * (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
- * (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
- * (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
- * (6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

(d) **Stimulants**: unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(1)	Pyrovalerone	1485-(3-88)
(2)	<pre>Ephedrine:a -{-(Methylamino)ethyl}benzene-methanol;</pre>	(10-95)
	a-{-(methylamino) ethyl}benzyl alcohol;	
	2-methylamino-1-phenyl-1-propanol;	
	1-phenyl-1-hydroxy-2-methylaminopropane;	
	1-phenyl-2-methylaminopropanol;	
	a - hydroxy-b-methylaminopropylbenzene;	
	a product which occurs in the Chinese herb	
	Ma Huang (Ephedra vulgaris, Ephedra sinica Stapf.,	
	Ephedra equisetina Bunge, Gnetaceae) in several	
	other Ephedra spp.	
(3)	Phenylpropanolamine	(7 - 05)
(4)	Pseudoephedrine	(7-05)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(e) **Depressants**: Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1)	Pregabalin [(S)-3-(aminomethyl)-	
	5-methylhexanoic acid)	2782-(01-06)
(1)	[Reserved]	
(2)	Lacosamide	2746 - (05 - 09)

Schedule VI**

(a) Any material, compound, mixture, or preparation, whether produced directly or indirectly from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, which contains any quantity of the following substances, or which contains any of their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation are included in Schedule VI:

chemical designation are included in schedule vi.	
(1) Marihuana	7360*
(2) Tetrahydrocannabinols	7 <u>3</u> 70*
-Meaning tetrahydrocannabinols naturall	y contained in a plant
of the genus Cannabis (cannabis plant)	,
(3) A synthetic equivalent of the substane	e contained in the cannabis
plant,	
or the substance contained_in the resi	nous extractives of the genus
Cannabis	-
(4) A substance with the chemical structure	of:
(A) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3	
or otherwise known by CP-47,497;	s mydromycycronemyr] pnener
(B) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-	hydroxycyclohexyl]-5 phenol
or otherwise known by either cannabicyclohexan	
- (C) 1-Butyl-3- (1-naphthoyl) indole or ot	herwise known by JWH-073;
- (D) 1=[2-(4-Morpholinyl)cthyl]-3-(1-nap	
known by JWH-200;	
(E) 1-Pentyl-3-(1-naphthoyl)indole or o	thorwise known by TWH-018 and
AM678;	enerwise known by own oro and
(F) (4-methoxy-1-naphthalenyl) (1-pentyl	-14-indol-3-vl)-mothanono or
otherwise known by JWH-081; or	in indoi 5 yr, meenanone or
- (G) 1-(1-pentyl-1H-indol-3-yl)-2-(2-met	howmhonul) - other or
otherwise known by JWH-250;	noxyphenyr, cenanone or
$\frac{(II)}{(II)} \begin{pmatrix} 1 \\ 5 \\ -1 \\ -1 \\ -1 \\ -1 \\ -1 \\ -1 \\ -$	(2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2
(H) (1-(5-flouropentyl)-1H-indol-3-yl)	(2,2,3,3)
tetramethylcyclopropyl)-methanone; XLR11	includes all ments of the
(5) Salvia divinorum or Salvinorin A, which	
plant presently classified botanically as Salv	
or not, the seeds of the plant, any extract fr	om any part of the plant, and
every compound, manufacture, derivative, mixtu	
plant, its seeds, or its extracts, including s	
isomers when the existence of the salts, isome	
possible within the specific chemical designat	
(6) A synthetic substances, derivatives, an	
(A) Similar chemical structure to any s	ubstance described in
subdivisions (a)(1)-(4) of this section or	
	any substance described in
subdivisions (a)(1)-(4) of this section such as the	following:
1 cis or trans tetrahydrocannabin	ol, and their optical
isomers. Excluding dronabinol	
encapsulated in a soft gelatin	capsule in a drug
product approved by the U.S. Fo	
6 cis or trans tetrahydrocannabin	
isomers.	-, and choir operedit

3, 4 cis or trans tetrahydrocannabinol, and its optical isomers.

(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)

(b) Provided, that the director shall not delete the controlled substances listed in this section from Schedule VI.

(a) In addition to any substance placed in Schedule VI by the Director of the Department of Health under § 5-64-214, any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation, is included in Schedule VI:

- (1) Marijuana
- (2) Tetrahydrocannabinols
- (3) A synthetic equivalent of:
 - (A) The substance contained in the Cannabis plant; or
 - (B) The substance contained in the resinous extractives of the genus Cannabis;
- (4) Salvia divinorum or Salvinorin A, which includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds of the plant, any extract from any part of the plant, and every compound, manufacture, derivative, mixture, or preparation of the plant, its seeds, or its extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation;
- (5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a) (5) (A) - (J) of this section and also specific unclassified substances in subdivision (a) (5) (K) of this section. Compounds of the structures described in this subdivision (a) (5), regardless of numerical designation of atomic positions, are included in this subdivision (a) (5). The synthetic substances, derivatives, or their isomers included in this subdivision (a) (5) are:
 - (A) (i) Tetrahydrocannabinols, including without limitation the following:
 - (a) Delta-1 cis or trans tetrahydrocannabinol, and its optical isomers;
 - (b) Delta-6 cis or trans tetrahydrocannabinol, and its optical isomers; and
 - (c) Delta-3.4 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (ii) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a) (5) (A)
 - (B) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(Nmethyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;

	(ii) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole;
	(iii) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole;
	(iv) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole;
	(v) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole;
	(vi) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl) indole;
	(vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-
	naphthoyl)indole
	(viii) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl) indole;
	(ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
	(x) JWH-200, or 1-[2-(4-morpholiny)ethyl]-3-(1-
	naphthoyl)indole;
	(xi) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole;
	(xii) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole;
	(xiii) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl) indole;
	(xiv) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-
	1-naphthalenyl)-methanone; and
	(xv) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-
	naphthalenyl)-methanone;
(C)	Naphthylmethylindoles, or any compound structurally derived
	from an H-indol-3-yl-(1-naphthyl) methane by substitution at
	the nitrogen atom of the indole ring by alkyl, haloalkyl,
	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
	piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or
	not further substituted in the indole ring to any extent and
	whether or not substituted in the naphthyl ring to any extent,
	including without limitation the following:
	(i) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane;
	and
	(ii) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-
	(ii) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1- naphthyl)methane;
(D)	naphthyl)methane;
	naphthyl)methane;
	naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from
	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of</pre>
	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,</pre>
	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-</pre>
	naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether
	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any</pre>
	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone;</pre>
	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3-</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl,</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, or 2-(4-morpholinyl)ethyl group, whether</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane;</pre>
(D)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylee)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl,</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl) indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindoles, or any compound structurally derived from derived from 3-phenylacetylindoles, or any compound structurally derived from piperidinylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl) indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent,</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl.cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, including without limitation the phenyl ring to any extent, including without limitation at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl.cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, including without limitation the following:</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl) indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylen)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: (i) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-</pre>
(D) (E)	<pre>naphthyl)methane; Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2- fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3- position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1- Naphthalenylmethylene)-1H-inden-3-yl]pentane; Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl.cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, including without limitation the phenyl ring to any extent, including without limitation at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl.cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, including without limitation the following:</pre>

- (iii) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole;
- (iv) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl)indole; and
- (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2methoxyphenylacetyl)indole;
- (G) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following:
 - (i) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3hydroxycyclohexyl]-phenol;
 - (ii) Cannabicyclohexanol or CP47,497 C8homologue, or 5-(1,1dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; and
 - (iii) CP55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol;
- (H) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:
 - (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
 - (ii) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole;
 - (iii) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2-
 - (iv) MM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2iodobenzoyl)indole; and
 - (v) RCS-4 (c4 homologue) or (4-methoxyphenyl)(1-butyl-1Hindol-3-yl)-methanone;
- (I) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantly ring to any extent, including without limitation the following: (i) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2
 - yl)methyl]indol-3-yl]methanone;
 - (ii) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone;
 - (iii) 2NE1, or 1-pentyl-3-(1-adamantylamido)indole;
 - (iv) JWH-018 adamantyl carboxamide, or 1-pentyl-Ntricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide; and
 - (v) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3carboxamide;
 - (vi) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-(5fluoropentyl)-1H-indazole-3-carboxamide;
 - (vii) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3carboxamide;
- (J) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-

		tetra	amethylcyclopropylcarbonyl) indole by substitution at the
		-	ogen atom of the indole ring with alkyl, haloalkyl,
			nyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
			palkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-
			nolinyl)ethyl, whether or not further substituted in the
		-	le ring to any extent, including without limitation the
			owing:
		(i)	UR-144, or (1-pentylindol-3-yl)-(2,2,3,3-
			tetramethylcyclopropyl)methanone;
		(ii)	XLR11, or [1-(5-fluoropentyl)-1H-indol-3yl]-(2,2,3,3-
			tetramethylcyclopropyl)methanone;
		(iii)	A-796260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-
			<pre>yl](2,2,3,3-tetramethylcyclopropyl)methanone;</pre>
		(iv)	5-Chloro-UR-144, or ([-(5-chloropentyl)-1H-indol-3-
			<pre>y1](2,2,3,3-tetramethylcyclopropyl)methanone;</pre>
		(v)	5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-
			<pre>y1](2,2,3,3-tetramethylcyclopropyl)methanone; and</pre>
		(vi)	A-834 735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-
			<pre>yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; or</pre>
	(K)	Uncla	assified Synthetic Cannabinoids, including without
			tation the following:
		(i)	CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9-hydroxy-
			6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-
			5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
		(ii)	HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
		<u>(/</u>	(2-methyloctan-2-yl)-6a,7,10,10a-
			tetrahydrobenzo[c]chromen-1-ol;
		(iii)	HU-211, or Dexanabinol, (6aS, 10aS, 10aS) -9- (hydroxymethyl) -
		(+++)	6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
			tetrahydrobenzo[c]chromen-1-ol;
		(iv)	Dimethylheptylpyran or DMHP;
		(v)	WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-
		(•)	morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-
			1-naphthalenylmethanone;
		(vi)	URB-597, or [3-(3-carbamoylphenyl)phenyl] N-
		(V I)	cyclohexylcarbamate;
		(i)	URB 754, or 6-methyl-2-[(4-methylphenyl)amino]-1-
		(V I I)	benzoxazin-4-one;
		(AKB-48, or N-(1-adamantyl)-1-pentylindazole-3-
		()	<u>carboxamide;</u>
		(ix)	CB 13, or 1-naphthalenyl[4-(pentyloxy)-1-naphthalenyl]-
		()	methanone;
		(x)	URB 602, or cyclohexyl N-(3-phenylphenyl)carbamate;
		(xi)	PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3-
		,	carboxylate;
		(X11)	5FPB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
			carboxylate;
		(X111)BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
		(xiv)	<u>carboxylate;</u> NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-
			carboxamide; and
		(xv)	5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-
			indole-3-carboxamide; or
(6)	A s	ynthet	ic substance, derivative, or its isomers with:
	(A)		lar chemical structure to any substance described in
		subdi	visions (a)(1)-(5) of this section; or

(B) Similar pharmacological effects to any substance described in subdivisions (a) (1)-(5) of this section.

(b) However, director shall not delete a controlled substance listed in this section from Schedule VI.

*-Scheduled before April, 1979. **-Schedule VI is revised to conform to Act 329 of 2013.